By Ilan Zipkin
Staff writer

EntreMed Inc. has decided to push into human trials with a compound that partner Bristol-Myers Squibb Co. believes is not ready for clinical development, reflecting the differing sense of urgency between a biotech company with nothing in the clinic and a pharma company with product sales and a broad oncology pipeline.